Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01239797
Completed
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Lymphoma, Multiple Myeloma
Register for Updates
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
NCT04452565
Unknown
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2022
Locations: Coronavirus Research Institute-Testing Site, Ann Arbor, Michigan +1 locations
Conditions: Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Register for Updates
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
NCT01078454
Completed
This randomized phase III trial is studying melphalan and dexamethasone to see how well they work with or without bortezomib in treating patients with previously untreated systemic amyloidosis. Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of plasma cells by blocking some of the enzymes needed for cell growth. It is not yet kn... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2022
Locations: University of Michigan, Ann Arbor, Michigan +7 locations
Conditions: Light Chain Deposition Disease, Primary Systemic Amyloidosis
Register for Updates
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
NCT01109004
Completed
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy or single autologous transplant plus maintenance therapy as part of upfront treatment of multiple myeloma (MM). Lenalidomide will be used as maintenance therapy for three years in all arms.
Gender:
ALL
Ages:
70 years and below
Trial Updated:
12/08/2021
Locations: University of Michigan Medical Center, Ann Arbor, Michigan +1 locations
Conditions: Multiple Myeloma
Register for Updates
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
NCT00075829
Completed
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending on the availability of an HLA-matched sibling. There is a nested randomized phase III trial of observation versus maintenance therapy following the second autologous transplant for patients on the ta... Read More
Gender:
ALL
Ages:
70 years and below
Trial Updated:
10/19/2021
Locations: University of Michigan Medical Center, Ann Arbor, Michigan
Conditions: Multiple Myeloma
Register for Updates
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01412879
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy also work in different ways to kill more cancer cells or stop them from growing. It is not yet known whether rituximab is more effective with combination chemotherapy or bendamustine hydrochloride in treating patients wit... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2021
Locations: Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan +2 locations
Conditions: Lymphoma
Register for Updates
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
NCT02951819
Completed
The purpose of this study is to evaluate complete response plus (+) very good partial response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD), in previously untreated subjects, and in relapsed subjects with multiple myeloma, as defined by the International Myeloma Working Group (IMWG) criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2021
Locations: Not set, Grand Rapids, Michigan
Conditions: Multiple Myeloma
Register for Updates
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
NCT04882163
Withdrawn
This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based chemotherapy (Cohort C)) for participants with relapsed or refractory aggressive B-cell lymphoma (R/R a-BCL). All 3 cohorts will be open for enrollment at study start. Part 1 (dose escalation) will be followed by Part 2 (dose expansion), in which participants will be randomized... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2021
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Lymphoma, B-Cell
Register for Updates
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00651261
Unknown
The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to find out which is better. This research is being done because it is unknown whether the addition of midostaurin to chemotherapy treatment is better than chemotherapy treatment alone. Midostaurin has been tested in over 400 patients and is being studied in a number of ill... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
08/16/2021
Locations: Battle Creek Health System Cancer Care Center, Battle Creek, Michigan +10 locations
Conditions: Leukemia
Register for Updates
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
NCT02516423
Unknown
This randomized phase III trial compares ixazomib citrate, lenalidomide, dexamethasone and zoledronic acid with zoledronic acid alone to see how well they work when given after radiation therapy in treating patients with solitary plasmacytoma of bone. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Dexamethasone is a drug used in chemotherapy that may ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2021
Locations: Hickman Cancer Center, Adrian, Michigan +67 locations
Conditions: Solitary Osseous Plasmacytoma
Register for Updates
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
NCT01794507
Completed
The primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and the recommended phase two dose (RPTD) of ABT-199 when administered in subjects with relapsed /refactory multiple myeloma who are receiving bortezomib and dexamethasone as their standard therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/29/2021
Locations: University of Michigan Hospitals /ID# 80353, Ann Arbor, Michigan
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
NCT03033511
Terminated
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2021
Locations: Henry Ford Health System /ID# 156712, Detroit, Michigan +1 locations
Conditions: Small Cell Lung Cancer
Register for Updates